ESMCOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends June 30
ESCALON MEDICAL CORP
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Oct 13, 2026
$0.18+0.01 (+7.65%)
Close on Oct 19, 2026
- Market cap
- $2.72M
- P/E (TTM)
- 0.7
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
43.7%+1.5 pts over 5 years
Operating margin
0.4%+0.7 pts over 5 years
Net margin
31.5%+32.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.7% | +1.5% | +4.0% | +1.0% | |
| Gross profit | +1.1% | +0.5% | +4.7% | +0.3% | |
| Operating income | -66.0% | -54.4% | – | – | |
| Net income | +3702.5% | +106.3% | – | – | |
| EPS, diluted | – | +108.0% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -47.0% | -3.5% | 102.3% | |
| Return on assets | -13.8% | -0.9% | 56.8% | |
| Current ratio | 1.38 | 1.35 | 2.94 | |
| Interest coverage | -6.2× | -1.5× | 6.1× | |
| Inventory turnover | 3.0× | 3.8× | 3.7× | |
| Capex to revenue | 0.0% | 0.1% | 0.0% | |
| Diluted shares | 8M | 7M | 15M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Escalon Medical generated $2.76M from operations and spent $55.27K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$2.76M
Used
$55.27K
Capital expenditure$55.27K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin31.5%
×Asset turnover1.80×
×Equity multiplier1.80×
=Return on equity, FY2026102.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 31.5% | 1.80× | 1.80× | 102.3% |
| FY2025 | 0.9% | 2.47× | 2.62× | 5.7% |
| FY2024 | -1.0% | 2.38× | 2.69× | -6.7% |
| FY2023 | 3.8% | 2.32× | 3.07× | 26.8% |
| FY2022 | 0.2% | 1.97× | 3.69× | 1.2% |
| FY2021 | -0.5% | 1.84× | 3.84× | -3.5% |
| FY2020 | -6.9% | 1.73× | 2.95× | -35.4% |
| FY2019 | -2.6% | 1.82× | 2.31× | -10.9% |
| FY2018 | 5.1% | 2.19× | 2.90× | 32.5% |
| FY2017 | -6.5% | 2.14× | 3.40× | -47.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
4of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero$4.01M
- Cash generatingOperating cash flow above zero-$402.60K
- Return on assets improvedROA up on the prior year2.2% → 80.4%
- Earnings backed by cashOperating cash flow above net income-$402.60K vs $4.01M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.72 → 2.94
- No dilutionShare count did not rise14M → 15M
- Gross margin improvedGross margin up on the prior year45.75% → 43.73%
- More efficientAsset turnover rose2.53 → 2.55